A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug

PHASE3CompletedINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

June 7, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

January 2, 2014

Conditions
Urinary Bladder, Overactive
Interventions
DRUG

Solifenacin Succinate Suspension

Children aged 5 to 11 years and adolescents aged 12 to 17 years received solifenacin succinate liquid suspension once a day orally via syringe for 12 weeks along with non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB. The initial dose started with the equivalent of 5 mg in adults, referred to as pediatric equivalent dose (PED) of 5 mg (PED5), based on body weight for three weeks and was titrated up or down in up to three titration steps of three weeks each to reach the optimal dose. Titration up or down could lead to weight-based doses equivalent to doses in adults of 2.5 mg, 5 mg, 7.5 mg or 10 mg once daily and were referred to as PED2.5, PED5, PED7.5 and PED10. The minimum dose was PED2.5, and the maximum dose was PED10. The decision to titrate up or down was made by the investigator using information from the 7 day patient diary.

DRUG

Placebo

Children aged 5 to 11 years and adolescents aged 12 to 17 years received matching placebo liquid suspension once a day orally via syringe for 12 weeks along with non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB. The initial dose started with the equivalent of 5 mg in adults, referred to as pediatric equivalent dose (PED) of 5 mg (PED5), based on body weight for three weeks and was titrated up or down in up to three titration steps of three weeks each to reach the optimal dose. Titration up or down could lead to weight-based doses equivalent to doses in adults of 2.5 mg, 5 mg, 7.5 mg or 10 mg once daily and were referred to as PED2.5, PED5, PED7.5 and PED10. The minimum dose was PED2.5, and the maximum dose was PED10. The decision to titrate up or down was made by the investigator using information from the 7 day patient diary.

BEHAVIORAL

Urotherapy

Non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB.

Trial Locations (46)

1103

Site: 3850, Kiev

1108

Site: 6301, Quezon City

2020

Site: 3202, Antwerp

2650

Site: 3209, Antwerp

3000

Site: 3205, Leuven

4530

Site: 5202, Mexico City

4600

Site: 4504, Køge

5021

Site: 4701, Bergen

6000

Site: 3208, Charleroi

Site: 4502, Kolding

6100

Site: 9001, Ankara

7030

Site: 4702, Trondheim

7700

Site: 2703, Cape Town

8200

Site: 4501, Aarhus N

8500

Site: 3204, Kortrijk

9000

Site: 3201, Ghent

Site: 3203, Ghent

11883

Site: 4602, Stockholm

12208

Site: 1015, Albany

21000

Site: 3812, Novi Sad

35100

Site: 9002, Izmir

41685

Site: 4606, Gothenburg

49100

Site: 3853, Dnipropetrovsk

54185

Site: 4603, Skövde

55185

Site: 4601, Jönköping

71106

Site: 1006, Shreveport

90185

Site: 4605, Umeå

110744

Site: 8207, Seoul

120752

Site: 8201, Seoul

156707

Site:8202, Seoul

705717

Site:8203, Daegu

13087-567

Site: 5507, Campinas

80240-060

Site: 5506, Curitiba

L8N 3Z5

Site: 1005, Hamilton

G1V 4G2

Site: 1001, Québec

DK-9000

Site: 4503, Aalborg

C.P.06700

Site: 5205, Mexico City

80-803

Site: 4805, Gdansk

80-952

Site: 4803, Gdansk

20-093

Site: 4804, Lubin

04-736

Site: 4801, Warsaw

11 000

Site: 3810, Belgrade

400-711

Site: 8206, Incheon

Unknown

Site: 3854, Kharkiv

LS1 3EX

Site: 4403, Leeds

S10 2TH

Site: 4401, Sheffield

All Listed Sponsors
lead

Astellas Pharma Europe B.V.

INDUSTRY

NCT01565707 - A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug | Biotech Hunter | Biotech Hunter